Department of Bioengineering, Rice University, 77005, Houston, TX USA.
Nanoscale Res Lett. 2013 Feb 12;8(1):72. doi: 10.1186/1556-276X-8-72.
Nanocarriers have been explored to improve the delivery of tumor antigens to dendritic cells (DCs). Gold nanoparticles are attractive nanocarriers because they are inert, non-toxic, and can be readily endocytosed by DCs. Here, we designed novel gold-based nanovaccines (AuNVs) using a simple self-assembling bottom-up conjugation method to generate high-peptide density delivery and effective immune responses with limited toxicity. AuNVs were synthesized using a self-assembling conjugation method and optimized using DC-to-splenocyte interferon-γ enzyme-linked immunosorbent spot assays. The AuNV design has shown successful peptide conjugation with approximately 90% yield while remaining smaller than 80 nm in diameter. DCs uptake AuNVs with minimal toxicity and are able to process the vaccine peptides on the particles to stimulate cytotoxic T lymphocytes (CTLs). These high-peptide density AuNVs can stimulate CTLs better than free peptides and have great potential as carriers for various vaccine types.
纳米载体已被探索用于提高肿瘤抗原递送至树突状细胞 (DC) 的效率。金纳米颗粒是一种很有吸引力的纳米载体,因为它们具有惰性、无毒且可以被 DC 轻易内吞。在这里,我们使用简单的自下而上的偶联方法设计了新型基于金的纳米疫苗 (AuNVs),以实现高肽密度的递呈和有效的免疫反应,同时毒性有限。AuNVs 是使用自组装偶联方法合成的,并使用 DC 向脾细胞 IFN-γ 酶联免疫斑点分析进行了优化。AuNV 设计成功地实现了约 90%的产率的肽偶联,同时直径仍保持在 80nm 以下。AuNVs 摄取 DC 具有最小的毒性,并且能够在颗粒上处理疫苗肽以刺激细胞毒性 T 淋巴细胞 (CTL)。这些高肽密度的 AuNVs 可以比游离肽更好地刺激 CTL,并且作为各种疫苗类型的载体具有巨大的潜力。
ACS Appl Mater Interfaces. 2013-4-22
Int J Nanomedicine. 2012-3-15
Surg Oncol Clin N Am. 2002-7
Bioconjug Chem. 2018-2-13
J Control Release. 2017-4-18
J Nanotheranostics. 2024-6
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025
ACS Nanosci Au. 2024-2-14
Pharmaceutics. 2023-9-19
Nanoscale Adv. 2020-8-24
Bioconjug Chem. 2012-3-30
Nanoscale Res Lett. 2011-4-4
J Immunol. 2011-2-1
Pharm Res. 2010-8-19
Mol Immunol. 2009-2
Crit Rev Oncol Hematol. 2008-8